Using mouse models, Hyonchol Jang and Byung Il Lee at the National Cancer Center, Goyang, South Korea, and co-workers demonstrated that the drug BMS794833 is an effective inhibitor of MERTK-dependent efferocytosis. Here, MERTK is linked to cancer.